Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep;37(9):1689-1690.
doi: 10.1111/jdv.19287.

Advances in biologic therapy of psoriasis

Mark Lebwohl  1
Affiliations
Comment

Advances in biologic therapy of psoriasis

Mark Lebwohl. J Eur Acad Dermatol Venereol. 2023 Sep.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Curmin R, Guillo S, De Rycke Y, Bachelez H, Beylot-Barry M, Beneton N, et al. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2022;36(11):2101-12. https://doi.org/10.1111/jdv.18409
    1. Mastorino L, Susca S, Cariti C, Sliquini N, Verrone A, Stroppiana E. Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? J Eur Acad Dermatol Venereol. 2023;37:1849-53.
    1. Papp KA, Lebwohl MG. Onset of action of biologics in patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2018;17:247-50.
    1. Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258-69. https://doi.org/10.1001/jamadermatol.2019.4029
    1. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27-40. https://doi.org/10.1016/j.jaad.2018.06.057

LinkOut - more resources